AstraZeneca has agreed to acquire Gracell Biotechnologies, a China-based cell therapy developer, for up to $1.2 billion. The acquisition aims to increase AstraZeneca's investment in cell therapies for treating cancer. Centerview Partners acted as the exclusive financial advisor to Gracell on its sale to AstraZeneca. The deal includes a $10 per share plus $0.30 CVR, representing a ~60% premium on Friday's closing price. AstraZeneca's acquisition of Gracell Biotechnologies is part of the British drug giant's strategy to bolster its bets on medical innovation in China.
Itโs been a busy week for Big Pharma with $AZN & $BMY both announcing multi-billion dollar deals in the last 24 hours. @scottgottliebmd breaks down what these deals could mean for the industry as we head into 2024: https://t.co/lt6W6wuDDY
Astrazeneca $AZN to acquire Gracell $GRCL for $10/ADS plus non tradeable contingent value right
"#AstraZeneca is set to make one of its 1st acquisitions in #China, announcing plans to acquire Gracell Biotechnologies for up to $1.2B to increase its investment in cell therapies for treating cancer" https://t.co/IBddMfnfG2
AstraZeneca Plc to buy Chinese cancer drug developer Gracell Biotechnologies Inc. for up to $1.2 billion as the British drug giant bolsters its bets on medical innovation in China https://t.co/dp7pj1ymcN
#AstraZeneca Plc has agreed to acquire Chinese cell therapy developer Gracell Biotechnologies Inc. for as much as $1.2 billion as the British drug giant bolsters its bets on medical innovation in the worldโs second-biggest economy. #Cancer #China https://t.co/LPrzZ9a8IW
Anglo-Swedish pharma giant AstraZeneca will acquire China-based cell therapy biotech Gracell Biotechnologies for $1.2 billion. https://t.co/hcCKTbSJBw
AstraZeneca buys China-based Gracell for $1.2B https://t.co/fvJgnGscaR
$GRCL (+60.3% pre) AstraZeneca $AZN Acquires Gracell Biotechnologies (GRCL) for $10/sh plus $1.50/sh CVR - SI https://t.co/qi6MNqF12c
AstraZeneca set to make one of its first acquisitions in China https://t.co/7k0aICF7NJ
AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy Goals https://t.co/7BH8BvJSxM
AstraZeneca agrees to acquire Chinese cell therapy developer Gracell Biotechnologies for as much as $1.2 billion https://t.co/3dOx8Wuiv1
AstraZeneca $AZN to buy China-based CAR-T therapy company Gracell $GRCL in $1.2Bn deal; $10 per share plus $0.30 CVR; ~60% premium on Friday's closing price; https://t.co/HvHkgNG5TR
Centerview Partners acted as Exclusive Financial Advisor to Gracell on its sale to AstraZeneca https://t.co/jqrRZyYgE3
AstraZeneca to buy China-based Gracell Biotechnologies in US$1.2 billion deal - https://t.co/zCF7g3r6DL
3 Asian biotech deals this morning: $AZN acquires ๐จ๐ณ $GRCL for $1.0bn upfront+200m$ contingent #CART $JNJ licenses the *cleaved* TROP2 ADC LCB084 from ๐ฐ๐ทLegoChemBio for 100m$ upfront+200m$ optin fee+$1.4bn contingent+tiered royalties (ph1/2 recently started) $JNJ also gets the
AstraZeneca to buy China-based Gracell Biotechnologies in $1.2 bln deal https://t.co/xb3iRSUtXv https://t.co/0nx1zeMhwG